Press Releases

December 19, 2016

NantHealth to Present at the 35th Annual J.P. Morgan Healthcare Conference on January 9

Read More
December 16, 2016

NantHealth, Inc. Announces Pricing of $100 Million of 5.50% Convertible Notes

Read More
December 15, 2016

NantHealth, Inc. Announces Proposed $100 Million Convertible Notes Offering

Read More
December 13, 2016

NantHealth Expands Adoption of GPS CancerTM with New Florida Genomics Lab License and Successful Adoption by Florida Community Oncologists

Read More
December 13, 2016

NantHealth Added to Nasdaq Biotech Index

Read More
December 8, 2016

NantHealth, NantKwest and NantOmics Announce Availability of GPS Cancer™ and Phase I – III QUILT Trials Through the U.S. National Institutes of Health’s ClinicalTrials.gov

Read More
December 7, 2016

NantHealth And TransMed Systems Partner to Enable and Inform Community Oncologists of the Most Effective Tools and Technologies for Personalized Cancer Treatments Using GPS Cancer™

Read More
December 6, 2016

NantHealth Announces Exclusive Reseller Agreement for GPS Cancer™ with Oncotest-Teva in Israel

Read More
December 5, 2016

NantHealth Continues Global Expansion Of GPS Cancer™ By Bringing Advanced Molecular Profiling to Patients in the Middle East Through Partnership with Lunatus

Read More
November 7, 2016

NantHealth Reports 76% Increase in Total Q3 Net Revenue 2016 vs 2015, Gross Profit Triples

Read More
Looking for older Press Releases? Check out the full archive here.